Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3033 - Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): a mono-institutional prospective study


10 Sep 2017


Poster display session


Central Nervous System Malignancies


eleonora Bergo


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


E. Bergo1, G. Lombardi1, P. Del Bianco2, S. Dal Pos3, F. Berti4, L. Bellu4, A. Pambuku1, V. Zagonel1

Author affiliations

  • 1 Clinical And Experimental Department, Medical Oncology 1, Veneto Institute of Oncology, 35128 - Padova/IT
  • 2 Clinical Trials And Biostatistics Unit, And Molecular Immunology And Oncology Unit, Veneto Institute of Oncology, 35128 - Padova/IT
  • 3 Neuroradiology Unit, University Hospital of Padua, 35128 - Padova/IT
  • 4 Radiation Therapy And Nuclear Medicine Unit, Veneto Institute of Oncology, 35128 - Padova/IT


Abstract 3033


Almost all PTS with GBM treated with RT and TMZ relapse during or after treatment. We performed a prospective study to assess if deterioration of QoL, CF and PSY is a predictor of RPD.


PTS with newly histologically diagnosed GBM treated with RT and TMZ as first-line therapy and KPS>60 were enrolled. PTS received TMZ for 12 cycles or until unacceptable toxicity or progressive disease. All questionnaires were given to PTS for self-assessment before performing MRI. Macdonald criteria were used for radiological evaluation. We assessed QoL, CF and PSY before starting treatment, at the end of RT, and every 3 months until 9 months after the end of RT using EORTC-C30, BN-20, MMSE and HADS questionnaires. Brain MRI were performed at the same timepoints.


We prospectively enrolled 111 consecutive PTS at our oncological center, Veneto Institute of Oncology, between January 2013 and December 2015. Median age was 59; 69 PTS were male and 36 PTS aged ≥65. PTS showing a RPD reported lower physical functioning (p = 0.018), minor role function (p = 0.0007) and a lower global health status (p = 0.01) than patients without RPD. In addition, they reported greater uncertainty in the future (p = 0.007), increased drowsiness (p = 0.013), increased itchy skin (p = 0.005) and greater weakness in the legs (p = 0.027) compared to PTS without RPD. PTS with RPD were more anxious (p = 0.0021) and depressed (p = 0.0001) than PTS without RPD. The two groups significantly differed in CF (p = 0.0007), especially 1 and 6 months after RT, with worse results in the MMSE for PTS with RPD.


Worsening of QoL, CF and PSY can predict RPD in GBM PTS treated with RT and TMZ.

Clinical trial identification

Legal entity responsible for the study

Veneto Institute of Oncology




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.